Novo Nordisk’s Share Price Slide Sparks Debate Over Whether the Stock Is Now a Bargain
Novo Nordisk’s sharp market decline in 2025 has raised questions among investors about whether the pharmaceutical giant is facing lasting pressure or offering a rare buying opportunity amid strong long term demand for diabetes and obesity treatments.






